Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2007 05:39 ET | Source: Jerini AG

Jerini AG Reports Financial Results for Fiscal Year 2006

Highlights of 2006: * EUR 66.6 million in cash and cash equivalents as of December 31, 2006 * Increase in revenues to EUR 13.1 million from EUR 9.6 million in 2005 * Anticipated...
February 06, 2007 03:54 ET | Source: Jerini AG

Jerini Expands Collaboration With Baxter to Develop Non-Intraveneous Hemophilia Therapy

BERLIN, Feb. 6, 2007 (PRIME NEWSWIRE) -- Jerini AG announced today the expansion of their current research collaboration with Baxter AG for the development of a non-intravenous therapy for the...
November 14, 2006 02:59 ET | Source: Jerini AG

Jerini Reports Financial Results for First Nine Months

BERLIN, Nov. 14, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) reported financial results according to International Financial Reporting Standards (IFRS) for the first nine months ended September 30,...
October 05, 2006 08:56 ET | Source: Jerini AG

Jerini to Hold Press Conference at the European Academy of Dermatology and Venereology Congress in Rhodes, Greece

BERLIN, Oct. 5, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) announced today that Dr. Jochen Knolle, Chief Scientific Officer and Head of R&D at Jerini, and Dr. Adi Hoess, Chief Commercial Officer at...
September 21, 2006 19:49 ET | Source: Jerini AG

Jerini Hosts Conference Call on Phase III Clinical Trials of Icatibant for Hereditary Angioedema

BERLIN, Sept. 21, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) will host an audio webcast and conference call, including an open question and answer session, on Friday, September 22nd, 2006, to discuss...
September 21, 2006 16:50 ET | Source: Jerini AG

Jerini Announces Positive Results from Two Phase III Trials of Icatibant for the Treatment of Hereditary Angioedema

BERLIN, Sept. 21, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) announced today the results of its two pivotal Phase III trials (FAST-1 and FAST-2) for the subcutaneous treatment of hereditary angioedema...
July 03, 2006 07:11 ET | Source: Jerini AG

Jerini Announces the Election of Two New Supervisory Board Members

BERLIN, July 3, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) announced today the appointments of Zsolt Lavotha and Dr. Gunter Stock to Jerini's Supervisory Board, as elected at the company's June 30th...
June 07, 2006 03:09 ET | Source: Jerini AG

Jerini Completes Randomization of Last Patient in Phase III European Clinical Trial (FAST-2) of Icatibant for the Treatment of Hereditary Angioedema

-- Randomization now complete in both Phase III HAE trials -- A total of 130 patients randomized in FAST-1 and FAST-2 trials -- On track to report top line data in 3Q -- Filing of US and...
May 15, 2006 04:50 ET | Source: Jerini AG

Jerini AG Reports First Quarter Financial Results

BERLIN, May 15, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) reported financial results for its first quarter ended March 31, 2006. Under International Financial Reporting Standards (IFRS), revenues for...
May 02, 2006 05:21 ET | Source: Jerini AG

Jerini Appoints Andrew D. Curtis as Vice President U.S. Marketing for Jerini U.S., Inc.

BERLIN, May 2, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) announced the appointment of Andrew D. Curtis as Vice President U.S. Marketing, effective May 1, 2006. Curtis will be heading Jerini's recently...